Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.

Autor: Vadher K; Eli Lilly and Company, Bracknell, UK., Patel H; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana., Mody R; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana., Levine JA; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana., Hoog M; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana., Cheng AY; Division of Endocrinology and Metabolism, Department of Medicine, Trillium Health Partners and Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada., Pantalone KM; Department of Endocrinology, Cleveland Clinic, Cleveland, Ohio., Sapin H; Lilly France SAS, Neuilly-sur-Seine, France.
Jazyk: angličtina
Zdroj: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 Sep; Vol. 24 (9), pp. 1861-1868. Date of Electronic Publication: 2022 Jun 13.
DOI: 10.1111/dom.14775
Abstrakt: Aim: To conduct an adjusted indirect treatment comparison (aITC) of the efficacy of tirzepatide 5/10/15 mg versus semaglutide 2 mg in patients with type 2 diabetes.
Materials and Methods: The primary analysis was a Bucher aITC of the change from baseline at week 40 in HbA1c (%) and body weight (kg). Aggregate data from the SURPASS-2 study that met the HbA1c inclusion criterion of the SUSTAIN FORTE study and from SUSTAIN FORTE metformin-only treated patients were used for primary analysis.
Results: The SURPASS-2 refined population comprised 238/245/240 and 240 participants for tirzepatide 5/10/15 mg and semaglutide 1 mg, respectively. The SUSTAIN FORTE metformin-only population comprised 222 and 227 participants for semaglutide 1 and 2 mg, respectively. In this aITC, tirzepatide 10 and 15 mg significantly reduced HbA1c versus semaglutide 2 mg with an estimated treatment difference (ETD) of -0.36% (95% confidence interval [CI] -0.63, -0.09) and -0.4% (95% CI -0.67, -0.13), respectively. Tirzepatide 10 and 15 mg significantly reduced body weight versus semaglutide 2 mg with an ETD of -3.15 kg (95% CI -4.84, -1.46) and -5.15 kg (95% CI -6.85, -3.45), respectively. There were no significant differences between tirzepatide 5 mg and semaglutide 2 mg on change from baseline in HbA1c and body weight.
Conclusions: In this aITC, HbA1c and weight reductions were significantly greater for tirzepatide 10 and 15 mg versus semaglutide 2 mg and were similar for tirzepatide 5 mg versus semaglutide 2 mg. These findings provide comparative effectiveness insights in the absence of a head-to-head clinical trial.
(© 2022 Eli Lilly and Company. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: